Teva’s Zecuity migraine patch will be permanently pulled from the market due to safety reasons including the risk of serious burns and potential permanent scarring.
- Teva’s request to withdraw its approval of Zecuity by the FDA was approved effective today
To view the source of this information click
To contact the reporter on this story:
To contact the editor responsible for this story:
© 2020 Bloomberg L.P. All rights reserved. Used with permission.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.